Dicerna Pharmaceuticals Inc (DRNA) USD0.0001
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.